Personal CFO Solutions LLC Boosts Position in Teva Pharmaceutical Industries Ltd. $TEVA

Posted by Francis Steltz on Jul 10th, 2026

Personal CFO Solutions LLC raised its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report) by 248.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 31,483 shares of the company’s stock after buying an additional 22,441 shares during the period. Personal CFO Solutions LLC’s holdings in Teva Pharmaceutical Industries were worth $948,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Norges Bank acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth $1,098,060,000. Harel Insurance Investments & Financial Services Ltd. lifted its holdings in shares of Teva Pharmaceutical Industries by 19.2% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock valued at $1,402,945,000 after acquiring an additional 7,255,083 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Teva Pharmaceutical Industries by 39,228.4% during the 3rd quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock valued at $139,296,000 after acquiring an additional 6,878,304 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd lifted its holdings in shares of Teva Pharmaceutical Industries by 18.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock valued at $1,171,378,000 after acquiring an additional 5,917,423 shares in the last quarter. Finally, Schroder Investment Management Group boosted its position in Teva Pharmaceutical Industries by 261.1% during the 4th quarter. Schroder Investment Management Group now owns 7,426,885 shares of the company’s stock worth $231,793,000 after purchasing an additional 5,370,253 shares during the period. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on TEVA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th. Truist Financial boosted their price objective on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. UBS Group upped their target price on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. JPMorgan Chase & Co. increased their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Finally, Piper Sandler reiterated an “overweight” rating and set a $42.00 target price (up from $41.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, April 30th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $41.78.

Check Out Our Latest Stock Report on Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $33.09 on Friday. Teva Pharmaceutical Industries Ltd. has a 12 month low of $14.99 and a 12 month high of $37.35. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. The firm has a market capitalization of $38.04 billion, a P/E ratio of 24.88, a P/E/G ratio of 4.06 and a beta of 0.86. The company’s fifty day moving average price is $34.19 and its two-hundred day moving average price is $32.68.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last announced its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The company had revenue of $3.98 billion during the quarter. On average, research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.97 earnings per share for the current fiscal year.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 21,258 shares of the company’s stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $35.31, for a total value of $750,619.98. Following the transaction, the executive vice president directly owned 63,647 shares of the company’s stock, valued at $2,247,375.57. This represents a 25.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Amir Weiss sold 10,679 shares of the stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $36.00, for a total value of $384,444.00. Following the transaction, the chief accounting officer owned 20,016 shares of the company’s stock, valued at approximately $720,576. This trade represents a 34.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 465,931 shares of company stock valued at $16,332,989 in the last three months. 0.54% of the stock is currently owned by company insiders.

About Teva Pharmaceutical Industries

(Free Report)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.